PD-1/PD-L1 blockade

Overview

PD-1/PD-L1 blockade refers to therapeutic inhibition of the programmed cell death protein 1 (PD-1) receptor and its ligand PD-L1, an immune checkpoint axis that normally restrains T-cell activation. In physiology, this pathway helps maintain peripheral immune tolerance and limits excessive inflammation. In cancer and some inflammatory settings, however, PD-1/PD-L1 signaling can be co-opted to suppress cytotoxic T-cell function, promote T-cell dysfunction, and support immune escape.

As a biomedical target, PD-1/PD-L1 blockade is most widely associated with immunotherapy, but recent studies also examine its role in non-oncologic immune dysregulation, including sepsis. Across these contexts, blockade of the pathway is investigated as a way to restore immune homeostasis, enhance anti-tumor immunity, and counteract immunosuppression. Related mechanisms in the recent literature include PD-L1-mediated suppression of cytotoxic CD8+ T cells, PD-1-associated T-cell dysfunction in multiple myeloma, and checkpoint modulation alongside pathways such as signal transducer and activator of transcription 3 (STAT3) and β-catenin.

Recent Publications Summary

Recent publications on PD-1/PD-L1 blockade continued to define both its therapeutic potential and the mechanisms that limit response. In metastatic renal cell carcinoma, the sequence of treatment was shown to be critical: short-term axitinib preconditioning remodeled vasculature, reduced hypoxia and suppressive myeloid subsets, and created an immune-permissive window in which survivin vaccination followed by PD-1 blockade produced durable tumor control and a high rate of complete responses in an orthotopic mouse model 42343214Jun. In ovarian cancer, nanocrystalline berberine enhanced the antitumor activity of anti-PD-1 therapy, with combination treatment suppressing tumor growth more effectively than either agent alone and increasing intratumoral CD8+ T-cell abundance 42096996May. In hepatocellular carcinoma, intratumoral sodium bicarbonate potentiated PD-1 blockade by inducing intracellular alkalization, mitochondrial damage, cGAS-STING activation, and immunogenic cell death; in a prospective clinical study, tislelizumab plus intratumoral bicarbonate was associated with a high objective response rate and favorable tolerability 42243329Jun.

Several studies focused on resistance mechanisms and immune contexture associated with PD-1/PD-L1 blockade. In pancreatic cancer, PD-L1 immune checkpoint blockade promoted immune evasion through epigenetic Tap1 silencing and selection of metastatic variants with defective IFN-γ-inducible MHC-I expression, while depletion of regulatory T cells, transfer of tumor-reactive CD4 T cells, or anti-CTLA-4 prevented metastasis 42361199Jun. In colorectal cancer, tumor-intrinsic β-catenin palmitoylation by ZDHHC5 was reported to coordinate immune evasion by simultaneously upregulating SLC7A11 and PD-L1, and ZDHHC5 expression predicted poor survival and resistance to anti-PD-L1 therapy 42208545May. In clear cell renal cell carcinoma, FN1+ macrophages were linked to sarcomatoid differentiation and immunotherapy-refractory disease, and ex vivo assays evaluated FN1 blockade alone and in combination with PD-1 blockade 42249083Jun. A separate pancreatic cancer study identified the CDK1/Cyclin B1 complex as a tumor-intrinsic driver of immune evasion; its genetic or pharmacologic inhibition induced a T-cell-inflamed microenvironment and synergized with PD-1 blockade 41921857Apr.

Other reports examined biomarkers and immune phenotypes associated with response to PD-1/PD-L1 blockade. A prospective study in advanced NSCLC evaluated blood-based kinase activity profiling in peripheral blood mononuclear cells as a predictor of response to immune checkpoint blockade and compared its performance with PD-L1 tumor proportion score 42342406Jun. In advanced and recurrent cervical cancer, baseline CD4+ T-cell percentage and post-treatment CA125, SCCA, CD8+ T-cell percentage, and PD-1 expression on CD4+/CD8+ T cells were associated with treatment response and prognosis during first-line immunotherapy combined with chemo/radiotherapy 42334275Jun. A nationwide cohort of 2127 responders with melanoma, RCC, or NSCLC found that progression risk after PD-1/PD-L1 blockade was primarily stratified by response depth, with complete and partial responders showing similar progression-free survival trajectories across tumor types 42284973Jun. In multiple myeloma, a review highlighted the PD-1/PD-L1 axis as one contributor to T-cell dysfunction within the bone marrow microenvironment 42307688Jun.

Beyond oncology, PD-1/PD-L1 blockade was also explored in immune dysregulation and adverse-event settings. In immune checkpoint inhibitor-induced inflammatory arthritis, a subset of atypical regulatory T cells coexpressing CD137 and IL6R was enriched, displayed reduced suppressive capacity and a Th17-like phenotype, and was associated with more severe arthritis but improved cancer outcomes; off-label tocilizumab reduced these cells and alleviated arthritis while maintaining antitumor immunity in a small cohort 42383349Jul. In septic mice, moxibustion combined with anti-PD-1 antibody improved survival and immune parameters more than either monotherapy, including reversal of T-cell depletion and downregulation of PD-1/PD-L1 and STAT3 signaling 42307810Jun. An artificial exosome nano-decoy designed to home to senescent-like neutrophils also incorporated PD-1 to engage PD-L1, aiming to reduce T-cell exhaustion and restore immune homeostasis in sepsis 42140195May. In parallel, a PD-1-targeted IL-15 mutein was reported to block PD-1/PD-L1 and PD-1/PD-L2 interactions while selectively delivering IL-15 signals to PD-1+ T cells, enhancing CD8+ and CD4+ T-cell activation and restoring effector function in preclinical infection and cancer models 42060360Apr.

What Changes, What Holds

1. Treatment sequencing can create a temporary window in which PD-1 blockade works far better than it otherwise would
NEW DIRECTION Short-term vascular normalization and relief of hypoxia/suppressive myeloid pressure suggest that response to PD-1 blockade may depend heavily on microenvironmental priming, not just checkpoint inhibition itself 42343214Jun. The combination signal is stronger than simple add-on synergy: it implies that PD-1/PD-L1 blockade may need to be staged with other interventions to become effective in some tumors. The clinical bicarbonate data in hepatocellular carcinoma point in the same direction, but remain early 42243329Jun.

2. PD-L1 blockade can also drive immune escape when it reshapes tumor evolution under selective pressure
PARADIGM SHIFT This cuts against the baseline view of PD-1/PD-L1 blockade as a means to restore anti-tumor immunity, because the new work shows PD-L1 inhibition itself can promote metastatic immune evasion through Tap1 silencing and loss of IFN-γ-inducible MHC-I expression 42361199Jun. The evidence is preclinical and mechanistic, so it does not overturn the therapeutic class, but it does require that resistance and pro-escape effects be treated as part of the biology, not just failure to respond. The macrophage and CDK1/Cyclin B1 findings reinforce that context 42249083Jun41921857Apr.

3. Response assessment is moving beyond tumor PD-L1 toward blood-based immune state and depth of remission
METHOD Blood kinase profiling and circulating T-cell phenotyping refine how PD-1/PD-L1 blockade is monitored, rather than changing what the therapy is understood to do 42342406Jun42334275Jun. The cohort data also suggest that once a deep response is achieved, later progression risk may be more similar across tumor types than expected, which sharpens prognostic interpretation without altering the baseline mechanism 42284973Jun. The multiple myeloma review simply extends the established immune-dysfunction framework into another disease setting 42307688Jun.

4. PD-1/PD-L1 blockade is being repurposed as an immune-restorative tool in inflammatory disease and sepsis, but the field remains preclinical
NEW DIRECTION These studies extend the baseline beyond oncology by treating the axis as a target for reversing immune paralysis, T-cell depletion, and checkpoint-driven dysregulation in sepsis and checkpoint-inhibitor arthritis 42307810Jun42140195May42383349Jul. That does not contradict the established cancer use; it broadens the entity’s role into immune-homeostasis restoration and adverse-event management. The PD-1-targeted IL-15 mutein also suggests a more selective way to exploit the pathway, but its place remains experimental 42060360Apr.

Overview update candidates: treatment sequencing and microenvironmental priming; PD-L1 blockade as a potential driver of immune escape/resistance; PD-1/PD-L1 blockade in sepsis and inflammatory arthritis as immune-restorative or toxicity-modulating therapy.